Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

BioNexus Gene Lab (BGLC) Restructuring Costs (2020 - 2025)

BioNexus Gene Lab's Restructuring Costs history spans 6 years, with the latest figure at $445691.0 for Q3 2025.

  • For Q3 2025, Restructuring Costs rose 70.45% year-over-year to $445691.0; the TTM value through Sep 2025 reached $1.7 million, up 296.11%, while the annual FY2024 figure was $2.0 million, 19.19% down from the prior year.
  • Restructuring Costs for Q3 2025 was $445691.0 at BioNexus Gene Lab, down from $516790.0 in the prior quarter.
  • Across five years, Restructuring Costs topped out at $3.1 million in Q3 2023 and bottomed at -$2.0 million in Q4 2023.
  • The 5-year median for Restructuring Costs is $433985.0 (2021), against an average of $434070.2.
  • The largest annual shift saw Restructuring Costs surged 1276.84% in 2022 before it plummeted 506.52% in 2023.
  • A 5-year view of Restructuring Costs shows it stood at $433985.0 in 2021, then increased by 12.41% to $487858.0 in 2022, then tumbled by 506.52% to -$2.0 million in 2023, then soared by 115.48% to $306932.0 in 2024, then surged by 45.21% to $445691.0 in 2025.
  • Per Business Quant, the three most recent readings for BGLC's Restructuring Costs are $445691.0 (Q3 2025), $516790.0 (Q2 2025), and $391876.0 (Q1 2025).